Oculis Holding AG (OCS)
NasdaqGM · USD · Healthcare · Biotechnology
$7.96 (+0.76%) as of
Key statistics
- Market cap
- 490.24M
- Forward P/E
- -4.04
- EPS (TTM)
- -1.75
- Dividend yield
- 0.00%
- 52-week range
- 7.11 – 34.47
- Beta
- 0.26
- Revenue (TTM)
- 1.17M
- Profit margin
- 0.00%
- Analyst target
- $36.84
- Volume
- 206.96k
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zug, Switzerland
- Employees
- 60
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.